Li W - Search Results

1

3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.

Sheng Y, Li W, Zhu F, Liu K, Chen H, Yao K, Reddy K, Lim DY, Oi N, Li H, Peng C, Ma WY, Bode AM, Dong Z, Dong Z. Sheng Y, et al. Among authors: li w, li h. J Biol Chem. 2014 Oct 10;289(41):28192-201. doi: 10.1074/jbc.M114.593475. Epub 2014 Aug 13. J Biol Chem. 2014. PMID: 25122774 Free PMC article.

2

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX. Yin YM, et al. Among authors: li w. J Exp Clin Cancer Res. 2010 Sep 15;29(1):126. doi: 10.1186/1756-9966-29-126. J Exp Clin Cancer Res. 2010. PMID: 20843324 Free PMC article.

3

Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.

Chen X, Li W, Hu X, Geng Y, Wang R, Yin Y, Shu Y. Chen X, et al. Among authors: li w. Biomed Pharmacother. 2011 Dec;65(8):542-6. doi: 10.1016/j.biopha.2011.04.017. Epub 2011 Jun 12. Biomed Pharmacother. 2011. PMID: 21840160 Clinical Trial.

4

Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?

Zhao ZR, Li W, Long H. Zhao ZR, et al. Among authors: li w. Sci Rep. 2014 Aug 8;4:5996. doi: 10.1038/srep05996. Sci Rep. 2014. PMID: 25104233 Free PMC article.

5

[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].

Guan ZZ, Zhang L, Li LY, Jiang GL, Liu XY, Chu DT, Zhao HY, Li W. Guan ZZ, et al. Among authors: li ly, li w. Ai Zheng. 2005 Aug;24(8):980-4. Ai Zheng. 2005. PMID: 16086877 Clinical Trial. Chinese.

6

Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

Ju L, Zhou C, Li W, Yan L. Ju L, et al. Among authors: li w. J Cell Biochem. 2010 Dec 15;111(6):1565-74. doi: 10.1002/jcb.22888. J Cell Biochem. 2010. PMID: 21053345

7

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Wu YL, et al. Among authors: li w. Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15. Lancet Oncol. 2014. PMID: 24439929 Clinical Trial.

8

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.

Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, Wang F, Reindl KM, Wu E, Ma Q. Liu J, et al. Among authors: li w. BMC Cancer. 2014 Sep 20;14:686. doi: 10.1186/1471-2407-14-686. BMC Cancer. 2014. PMID: 25240403 Free PMC article.

9

Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients.

He Y, Li S, Ren S, Cai W, Li X, Zhao C, Li J, Chen X, Gao G, Li W, Zhou F, Zhou C. He Y, et al. Among authors: li s, li j, li w, li x. Lung Cancer. 2013 Aug;81(2):162-6. doi: 10.1016/j.lungcan.2013.05.004. Epub 2013 May 30. Lung Cancer. 2013. PMID: 23726438

10

[Nimotuzumab in combination with chemotherapy in patients with advanced non-small cell lung cancer].

Li LF, Wang HQ, Liu XM, Zhang HL, Qiu LH, Qian ZZ, Li W. Li LF, et al. Among authors: li w. Zhonghua Zhong Liu Za Zhi. 2011 Aug;33(8):626-8. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 22325226 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82,640 results

Search Page

Filters